Japan, 26th June 2025: Aerogen, the Ireland-based global leader in acute-care aerosol drug delivery, has announced new expansion and investment plans for its operations in Japan, to support medical advancements in treating all respiratory conditions. This strategic expansion underscores Aerogen’s commitment to support Japan’s healthcare sector by improving access to cutting-edge aerosol drug delivery solutions for all respiratory patients.
Aerogen recognises the importance in working with key institutions to collobrate on potnetial research to advance patient care within this sector, following the 2022 Japanese respiratory society guideline for the management of chronic obstructive pulmonary disease (6th edition), which recognises that COPD exacerbation requires significant healthcare expenditures and has become a major healthcare issue in Japan. Japanese patients with COPD have unique characteristics compared to patients in Western countries.
-wjvq0p.jpg)
Speaking at the EU-Japan Healthcare Conference, Peter Burke TD, Minister for Enterprise, Tourism and Employment said; “This strategic investment by Aerogen in this important market is a milestone, not only for the company, but it helps to further strengthen ties between Japan and Ireland, reinforcing our shared commitment to healthcare innovation. Aerogen’s decision to further invest in Japan, is a testament to the country’s rapidly advancing healthcare ecosystem. We look forward to fostering a borderless enterprise where bilateral collaboration in innovation and research benefits both Japan and Ireland.”
With a new office in Tokyo, it will serve as the operational hub for Aerogen’s growing team of experts in the Japanese market, and this team will include a country director, marketing professionals, commercial sales specialists, and clinical experts. With 10 team members at present, Aerogen plans to expand to approximately 30 employees over the next five years to support its growth and market penetration.
Highlighting Aerogen’s commitment to Japan, Hannah Yuill Senior Director APAC said, “Aerogen is dedicated to ensuring that hospitals and patients in Japan have access to the most advanced aerosol drug delivery systems. With Japan’s large ageing population and the increasing prevalence of respiratory diseases, our expansion is a crucial step in supporting the healthcare system in delivering superior patient care safely and effectively. This investment in Japan is a vital part of our strategy to expand across the APAC region and collaborate closely with healthcare professionals to improve respiratory treatment outcomes.”
Aerogen’s Japan expansion is a reflection of the robust economic ties between Ireland and Japan. The company’s global growth has been supported by Enterprise Ireland, the Irish government agency that helps Irish businesses scale internationally.
About Aerogen
About Aerogen
Headquartered in Galway, Ireland, Aerogen is a global leader in aerosol drug delivery systems, specializing in acute care. The company’s patented vibrating mesh technology converts liquid medications into fine aerosols, enabling efficient delivery to the lungs for critical care patients. With over 25 years of innovation, Aerogen's technology is trusted in more than 75 countries and has been used to treat over 16 million patients globally. Known for its high-performance devices, such as the Aerogen Solo, the company continues to expand its reach and workforce, with significant investments in research and development. Aerogen plays a crucial role in treating respiratory conditions and continues to advance healthcare solutions worldwide.
To know more about Aerogen, please visit: https://www.aerogen.com/
About Enterprise Ireland
Enterprise Ireland is the Irish government organization responsible for the development and growth of Irish enterprises in world markets. Enterprise Ireland works in partnership with Irish enterprises to help them start, grow, innovate and win export sales in global markets. In this way, the organization supports sustainable economic growth, regional development and secure employment. A key priority is the achievement of export sales growth and jobs for Irish-owned companies.
To know more about Enterprise Ireland, please visit: https://www.enterprise-ireland.com/en/
